49. Labriola RA, Tombari, Dora G.,Vecchioli, Adriana, inventor Gador S. A., assignee. Crystalline form of the Zoledronic Acid, a process to obtain it and the pharmaceutical composition compromising it. A.B.D.2008. 50. Lambrecht RM, Tomiyoshi K, Sekine T. Radionuclide generators. Radiochim Acta. 1997;77(1-2):103-23. 51. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther. 2003;25(11):2669-708. 52. Lin J, Qiu L, Cheng W, Luo S, Ye W. Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative. Nucl Med Biol. 2011;38(5):619-29. 53. Lin JG, Luo SN, Chen CP, Qiu L, Wang Y, Cheng W, et al. Preparation and preclinical pharmacological study on a novel bone imaging agent (99m)Tc-EMIDP. Appl Radiat Isotopes. 2010;68(9):1616-22. 54. Lipton A. Emerging role of bisphosphonates in the clinic–antitumor activity and prevention of metastasis to bone. Cancer Treat Rev. 2008;34 Suppl 1:S25-30. 55. Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99(9):2235-68. 56. Llana B, Nunez R, Roiz C, Raigoso P, Allende T, Sanchez A, et al. Assessment of cerebral perfusion with 99mTc-HMPAO-single photon emission computer tomography (SPECT) following carotid endarterectomy (CE). Eur J Nucl Med. 1999;26(9):1132-. 57. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro C. Radionuclide bone imaging: An illustrative review. Radiographics. 2003;23(2):341-58. 58. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-67. 59. Michael J. Welch CSR. Handbook of Radiopharmaceuticals: Radiochemistry and Applications2003. 60. Monroy-Guzman F, Diaz-Archundia LV, Ramirez AC. Effect of Zr : Mo ratio on Tc-99m generator performance based on zirconium molybdate gels. Appl Radiat Isotopes. 2003;59(1):27-34. 61. Morales AA, Crespo FZ, Gandolff GN, Iznaga Escobar N, Perez NP, Hernandez JC. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3. Nucl Med Biol. 1998;25(1):25-30. 62. Motaleb MA. Preparation, quality control and stability of 99mTc-sparafloxacin complex, a novel agent for detecting sites of infection. J Labelled Compd Rad. 2009;52(910):415-8. 63. Neves M, Gano L, Pereira N, Costa MC, Costa MR, Chandia M, et al. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nucl Med Biol. 2002;29(3):329-38. 64. Oh SJ, Ryu JS, Shin JW, Yoon EJ, Ha HJ, Cheon JH, et al. Synthesis of Tc-99mciprofloxacin by different methods and its biodistribution. Appl Radiat Isotopes. 2002;57(2):193-200. 65. Özgür Ö CK, Ömer U. Kas iskelet sistemi hastalıklarında nükleer tıp yöntemleri. Türk Ortopedi ve Travmatoloji Birliği Dergisi. 2007;6(1-2):1-29. 66. Palmedo H, Bender H, Schomburg A, Grunwald F, Schoneich G, Zamorra P, et al. Therapy with rhenium-186 HEDP in painful bone metastases. Nuklearmed. 1996;35(2):63-7. 67. Pauwels EK, Feitsma RI. Radiochemical quality control of 99mTc-labeled radiopharmaceuticals. Some daily practice guidelines. Eur J Nucl Med. 1977;2(2):97-103. 68. Perry CM, Figgitt DP. Zoledronic acid – A review of its use in patients with advanced cancer. Drugs. 2004;64(11):1197-211. 69. Peter F. Sharp HGG, Allison D. Murray, (Ed). Practical Nuclear Medicine. Third Edition ed. London: Springer-Verlag; 2005. 70. Poggenburg JK. The nuclear reactor and its products. Semin Nucl Med. 1974;4(3):229-43.
142



155. SAYFAYA BENZER SAYFALAR

tabs_sener_yagiz_191898 - Sayfa
...


155. SAYFA ICERIGI

49. Labriola RA, Tombari, Dora G.,Vecchioli, Adriana, inventor Gador S. A., assignee. Crystalline form of the Zoledronic Acid, a process to obtain it and the pharmaceutical composition compromising it. A.B.D.2008. 50. Lambrecht RM, Tomiyoshi K, Sekine T. Radionuclide generators. Radiochim Acta. 1997;77(1-2):103-23. 51. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther. 2003;25(11):2669-708. 52. Lin J, Qiu L, Cheng W, Luo S, Ye W. Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative. Nucl Med Biol. 2011;38(5):619-29. 53. Lin JG, Luo SN, Chen CP, Qiu L, Wang Y, Cheng W, et al. Preparation and preclinical pharmacological study on a novel bone imaging agent (99m)Tc-EMIDP. Appl Radiat Isotopes. 2010;68(9):1616-22. 54. Lipton A. Emerging role of bisphosphonates in the clinic–antitumor activity and prevention of metastasis to bone. Cancer Treat Rev. 2008;34 Suppl 1:S25-30. 55. Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99(9):2235-68. 56. Llana B, Nunez R, Roiz C, Raigoso P, Allende T, Sanchez A, et al. Assessment of cerebral perfusion with 99mTc-HMPAO-single photon emission computer tomography (SPECT) following carotid endarterectomy (CE). Eur J Nucl Med. 1999;26(9):1132-. 57. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro C. Radionuclide bone imaging: An illustrative review. Radiographics. 2003;23(2):341-58. 58. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-67. 59. Michael J. Welch CSR. Handbook of Radiopharmaceuticals: Radiochemistry and Applications2003. 60. Monroy-Guzman F, Diaz-Archundia LV, Ramirez AC. Effect of Zr : Mo ratio on Tc-99m generator performance based on zirconium molybdate gels. Appl Radiat Isotopes. 2003;59(1):27-34. 61. Morales AA, Crespo FZ, Gandolff GN, Iznaga Escobar N, Perez NP, Hernandez JC. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3. Nucl Med Biol. 1998;25(1):25-30. 62. Motaleb MA. Preparation, quality control and stability of 99mTc-sparafloxacin complex, a novel agent for detecting sites of infection. J Labelled Compd Rad. 2009;52(910):415-8. 63. Neves M, Gano L, Pereira N, Costa MC, Costa MR, Chandia M, et al. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nucl Med Biol. 2002;29(3):329-38. 64. Oh SJ, Ryu JS, Shin JW, Yoon EJ, Ha HJ, Cheon JH, et al. Synthesis of Tc-99mciprofloxacin by different methods and its biodistribution. Appl Radiat Isotopes. 2002;57(2):193-200. 65. Özgür Ö CK, Ömer U. Kas iskelet sistemi hastalıklarında nükleer tıp yöntemleri. Türk Ortopedi ve Travmatoloji Birliği Dergisi. 2007;6(1-2):1-29. 66. Palmedo H, Bender H, Schomburg A, Grunwald F, Schoneich G, Zamorra P, et al. Therapy with rhenium-186 HEDP in painful bone metastases. Nuklearmed. 1996;35(2):63-7. 67. Pauwels EK, Feitsma RI. Radiochemical quality control of 99mTc-labeled radiopharmaceuticals. Some daily practice guidelines. Eur J Nucl Med. 1977;2(2):97-103. 68. Perry CM, Figgitt DP. Zoledronic acid – A review of its use in patients with advanced cancer. Drugs. 2004;64(11):1197-211. 69. Peter F. Sharp HGG, Allison D. Murray, (Ed). Practical Nuclear Medicine. Third Edition ed. London: Springer-Verlag; 2005. 70. Poggenburg JK. The nuclear reactor and its products. Semin Nucl Med. 1974;4(3):229-43.
142




single.php